US biotechnology firm The Liposome Company has said that sales of its newly-launched product Abelcet (amphotericin B lipid complex) for the 1996 year-to-date in the USA and overseas have exceeded $6 million.
"The launch of Abelcet has been extremely well received by physicians in the USA," said Charles Baker, chairman and chief executive at TLC. "To date, we have sold Abelcet into about 80% of the 50 hospitals that are the largest users of amphotericin B," he added.
TLC was granted approval for the product in the USA in November last year (Marketletter November 27, 1995). Abelcet is also approved for marketing in the UK, Spain, Luxembourg and Iceland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze